<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302584</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MD 239/2016</org_study_id>
    <nct_id>NCT04302584</nct_id>
  </id_info>
  <brief_title>Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock</brief_title>
  <official_title>Comparison of Between Norepinephrine Alone Versus Norepinephrine / Vasopressin Combination for Resuscitation in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although norepinephrine is commonly used and is the recommended agent for the treatment of&#xD;
      hypotension in volume-resuscitated hyperdynamic septic shock, Low doses of vasopressin may be&#xD;
      added to norepinephrine to maintain arterial blood pressure in refractory septic shock and to&#xD;
      decrease exposure to norepinephrine. The aim of the work is to compare the effect of&#xD;
      norepinephrine alone and Norepinephrine/vasopressin combination on hemodynamics and tissue&#xD;
      perfusion in septic shock patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study which was performed on 90 adult of either sex in intensive care unit who developed&#xD;
      septic shock.45 patients in each group according to the drugs used, by the single blind&#xD;
      technique as the treating physician only is aware of the drugs used.&#xD;
&#xD;
      Group 1: patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min).&#xD;
&#xD;
      Group 2: patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min).&#xD;
      +Vasopressin infusion at the rate of (0.03 unit/min).&#xD;
&#xD;
      A comparison was done between both groups as regard:Hemodynamics,Tissue perfusion, C-Reactive&#xD;
      Protein (mg/L) ,WBC, UREA (mg/dL),CREATININE (mg/dl), NGAL (Neutrophil gelatinase associated&#xD;
      Lipocalin) (ng/ml). Comparison was done at baseline, then every 6 hours for 48 h as regard&#xD;
      hemodynamics and tissue perfusion, and at base line then, 24 h and 48 h as regard sepsis&#xD;
      biomarkers and renal biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 6, 2019</completion_date>
  <primary_completion_date type="Actual">January 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactate Level Lactate level • (central venous oxygen saturation)SVO2</measure>
    <time_frame>48 hours</time_frame>
    <description>mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scvo2</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NGAL, NGAL NGAL</measure>
    <time_frame>48 hours</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>28 days mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>48 hours</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Septic Shock</condition>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>NE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received IV Norepinephrine infusion starting with (0.1mcg/kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NE/VP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received IV Norepinephrine infusion (Starting with (0.1 mcg/kg/min). +Vasopressin infusion at the rate of (0.03 unit/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norepinephrine / Vasopressin</intervention_name>
    <description>• The drug infusion was prepared as 100 IU of AVP (Pressyn; Ferring Inc., Toronto, Ontario, Canada) in 250 ml D5W, infused at the rate of 4.5 ml/h for 0.03 IU/min and 15 mg of Norepinephrine (Arterenol; Sanofi-Aventis, Frankfurt, Germany) in 250 ml D5W infused at the rate of 10 ml/h for 10 mcg/min using infusion pump.</description>
    <arm_group_label>NE</arm_group_label>
    <arm_group_label>NE/VP</arm_group_label>
    <other_name>norepinephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years of both sex&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with renal impairment (Creatinine&gt;2mg/dl)&#xD;
&#xD;
          -  Sever Heart Disease (ischemic/valvular)&#xD;
&#xD;
          -  Peripheral vascular disease (e.g. Raynaud's phenomenon)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hanaa El Gendy</name>
      <address>
        <city>Cairo</city>
        <state>Ain Shams University Specialized Hospital</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>March 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Hanaa Mohamed Abdallah ElGendy MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

